Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Received Truth Turned On End In Cancer Research

06.04.2004


It has long been the accepted view of cancer researchers that there is a difference between the mechanism behind the development of leukemias, on the one hand, and solid tumors like breast cancer, prostate cancer, gastrointestinal cancer, etc, on the other. A research team at the Section for Clinical Genetics at Lund University in Sweden is now claiming just the opposite: the same mechanism gives rise to all non-hereditary forms of cancer. These findings are being published in Nature Genetics.



A well-known mechanism for the development of cancer is that the chromosomes in a cell break apart and then recombine in an incorrect way. At the points of fissure, gene fragments are exposed that can recombine with so-called fusion genes, yielding fusion proteins. Leukemias--blood cancer--normally develop from cells that contain such fusion proteins. It is not known how this occurs in detail, but in some way the fusion proteins prompt formerly normal cells to transform into cancer cells. On the other hand, solid tumors, which make up the majority of all cancer cases, have been seen as developing as a result of certain cells losing the inhibiting mechanism in the form of so-called tumor suppressor genes that keep tumors from arising.

“This is no doubt correct in regard to hereditary cancer. But hereditary cancer accounts for only 5-10 percent of all cancer cases. We now maintain that all of the others have the same developmental mechanisms. In non-hereditary cancer forms it is the occurrence of fusion genes and not the lack of tumor suppressor genes that is essential,” says Professor Felix Mitelman.


Mitelman and his associates Bertil Johansson and Fredrik Mertens have gathered information about aberrant chromosomes in cancer for years. In 1997 Nature Genetics devoted an entire issue to the large material the Lund team had compiled, something that has only happened on one other occasion (when the human genome was presented). This material is now available as a large and constantly growing database in the so-called Cancer Genome Anatomy Project at the US National Cancer Institute, called the Mitelman Database of Chromosome Aberrations in Cancer.

In leukemia cells it is rather easy to find fusion genes and fusion proteins. For technical reasons, this is much more difficult in solid tumors.

“And if you haven’t seen them, you assume that they’re not there. But what has been lacking is appropriate methods of examination,” claims Felix Mitelman.

The research team has found that the number of fusion genes in solid tumors stands in the same proportion to the number of patient cases examined with leukemias. This shows that the same mechanisms are involved: the chance of this match being coincidental is less than 0.0001.

The good thing about this discovery is that it should lead to more effective treatment of the major cancer forms. For one type of leukemia, at any rate, there is a medicine that specifically targets the active fusion protein, and it is both effective and mild.

The downside is that there are probably a very great number of different fusion genes behind the major forms of cancer. Each transformation of genes is found in just a few patients.

“Small groups of patients are not of interest to pharmaceutical companies. On the other hand, it may be that several fusion proteins have common traits that make it possible to use the same drug to combat them,” hopes Felix Mitelman.

The fact that his research team have now turned on end an established truth does not mean that other ongoing research on the significance of genetic factors in the emergence of cancer has also been overturned, he emphasizes. Much of this research is about the long road from the first cancer cell to a full-blown tumor, and in this process tumor suppressor genes are probably of great importance. What the Lund team has done is to provide a revolutionary new picture of how this very first cancer cell arises.

Ingela Björck | alfa
Further information:
http://www.lu.se/info/pm/698_pressm.html

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>